Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients with Versus Without Chronic Kidney Disease

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Thrombotic events while receiving antiplatelet agents (APAs) are more common in subjects with versus without chronic kidney disease (CKD). Data on antiplatelet effects of APA in CKD are scarce and limited by lack of baseline platelet function before APA treatment. We hypothesized subjects with stages 4 to 5 CKD versus no CKD have greater baseline platelet aggregability and respond poorly to aspirin and clopidogrel. In a prospective controlled study, we measured whole blood platelet aggregation (WBPA) in 28 CKD and 16 non-CKD asymptomatic stable outpatients not on APA, frequency-matched for age, gender, obesity, and diabetes mellitus. WBPA was remeasured after 2 weeks of each aspirin and aspirin plus clopidogrel. The primary outcome was percent inhibition of platelet aggregation (IPA) from baseline. The secondary outcome was residual platelet aggregability (RPA; proportion with

Original languageEnglish (US)
Pages (from-to)656-663
Number of pages8
JournalAmerican Journal of Cardiology
Volume117
Issue number4
DOIs
StatePublished - Feb 15 2016

Fingerprint

clopidogrel
Chronic Renal Insufficiency
Platelet Aggregation
Aspirin
Platelet Aggregation Inhibitors
Blood Platelets
Kidney Diseases
Diabetes Mellitus
Outpatients
Obesity
Prospective Studies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{74051635af8148a88d3cdc8557761930,
title = "Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients with Versus Without Chronic Kidney Disease",
abstract = "Thrombotic events while receiving antiplatelet agents (APAs) are more common in subjects with versus without chronic kidney disease (CKD). Data on antiplatelet effects of APA in CKD are scarce and limited by lack of baseline platelet function before APA treatment. We hypothesized subjects with stages 4 to 5 CKD versus no CKD have greater baseline platelet aggregability and respond poorly to aspirin and clopidogrel. In a prospective controlled study, we measured whole blood platelet aggregation (WBPA) in 28 CKD and 16 non-CKD asymptomatic stable outpatients not on APA, frequency-matched for age, gender, obesity, and diabetes mellitus. WBPA was remeasured after 2 weeks of each aspirin and aspirin plus clopidogrel. The primary outcome was percent inhibition of platelet aggregation (IPA) from baseline. The secondary outcome was residual platelet aggregability (RPA; proportion with",
author = "Nishank Jain and Xilong Li and Beverley Adams-Huet and Ravi Sarode and Toto, {Robert D.} and Subhash Banerjee and Hedayati, {S. Susan}",
year = "2016",
month = "2",
day = "15",
doi = "10.1016/j.amjcard.2015.11.029",
language = "English (US)",
volume = "117",
pages = "656--663",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients with Versus Without Chronic Kidney Disease

AU - Jain, Nishank

AU - Li, Xilong

AU - Adams-Huet, Beverley

AU - Sarode, Ravi

AU - Toto, Robert D.

AU - Banerjee, Subhash

AU - Hedayati, S. Susan

PY - 2016/2/15

Y1 - 2016/2/15

N2 - Thrombotic events while receiving antiplatelet agents (APAs) are more common in subjects with versus without chronic kidney disease (CKD). Data on antiplatelet effects of APA in CKD are scarce and limited by lack of baseline platelet function before APA treatment. We hypothesized subjects with stages 4 to 5 CKD versus no CKD have greater baseline platelet aggregability and respond poorly to aspirin and clopidogrel. In a prospective controlled study, we measured whole blood platelet aggregation (WBPA) in 28 CKD and 16 non-CKD asymptomatic stable outpatients not on APA, frequency-matched for age, gender, obesity, and diabetes mellitus. WBPA was remeasured after 2 weeks of each aspirin and aspirin plus clopidogrel. The primary outcome was percent inhibition of platelet aggregation (IPA) from baseline. The secondary outcome was residual platelet aggregability (RPA; proportion with

AB - Thrombotic events while receiving antiplatelet agents (APAs) are more common in subjects with versus without chronic kidney disease (CKD). Data on antiplatelet effects of APA in CKD are scarce and limited by lack of baseline platelet function before APA treatment. We hypothesized subjects with stages 4 to 5 CKD versus no CKD have greater baseline platelet aggregability and respond poorly to aspirin and clopidogrel. In a prospective controlled study, we measured whole blood platelet aggregation (WBPA) in 28 CKD and 16 non-CKD asymptomatic stable outpatients not on APA, frequency-matched for age, gender, obesity, and diabetes mellitus. WBPA was remeasured after 2 weeks of each aspirin and aspirin plus clopidogrel. The primary outcome was percent inhibition of platelet aggregation (IPA) from baseline. The secondary outcome was residual platelet aggregability (RPA; proportion with

UR - http://www.scopus.com/inward/record.url?scp=84958892663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958892663&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.11.029

DO - 10.1016/j.amjcard.2015.11.029

M3 - Article

VL - 117

SP - 656

EP - 663

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 4

ER -